Biogen Announces Board Chair Transition Caroline Dorsa to retire from the Biogen Board of Directors; Dr. Maria C. Freire, Director since 2021, elected as new Chair CAMBRIDGE, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- . (Nasdaq: BIIB) today announced that the Board of Directors has elected Dr. Maria C. Freire as Chair of the Board of Directors, effective immediately following the Company’s 2026 Annual Meeting of Stockholders (the “Annual Meeting”), scheduled to take place on June 9, 2026. Dr. Freire will succeed Caroline Dorsa who has decided to retire from the Biogen Board of Directors a...
Nature Medicine Publishes Results from the Pivotal DEVOTE Study of High-Dose Regimen of Nusinersen in Spinal Muscular Atrophy Findings from DEVOTE support clinical benefits of the high-dose regimen of nusinersen (50 mg and 28 mg) in both treatment-naïve individuals and those previously treated with 12 mg nusinersenThe high-dose regimen of nusinersen also slowed neurodegeneration more rapidly, as measured by neurofilament, than the 12 mg regimen CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Inc. (Nasdaq: BIIB) today announced that published results from the Phase 2/3 DEVOTE study ...
Minerals Technologies Inc. Announces 2025 Fourth Quarter and Full Year Financial Results NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Minerals Technologies Inc. (NYSE: MTX) (“MTI”), a leading, technology-driven specialty minerals company, today reported earnings per share for the fourth quarter ended December 31, 2025, of $1.19, or $1.27 excluding special items. “This past year, MTI demonstrated our strength as a company through the resilience and ingenuity of our teams around the world. We navigated multiple market challenges while remaining focused on our growth projects and strategic...
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options Designation is based on the breadth of available litifilimab data, including the Phase 2 LILAC study result that showed improvements in cutaneous lupus erythematosus (CLE) skin disease activityLitifilimab has the potential to be a first-in-class therapy targeting blood dendritic cell antigen 2 (BDCA2) in CLE, a chronic autoimmune skin disease that has a substantial impact on the daily life of patients, and may result in permanent scarring and dis...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.